A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion.
10.3803/EnM.2015.30.4.481
- Author:
Camilla SCHALIN-JANTTI
1
;
Merja RAADE
;
Esa HAMALAINEN
;
Timo SANE
Author Information
1. Department of Endocrinology, Abdominal Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. camilla.schalin-jantti@hus.fi
- Publication Type:Original Article
- Keywords:
Adrenal incidentaloma;
Follow-up;
Computed tomography;
Pheochromocytoma;
Metanephrine;
Normetanephrine
- MeSH:
Adenoma;
Cushing Syndrome;
Follow-Up Studies*;
Humans;
Hyperaldosteronism;
Mass Screening;
Metanephrine;
Normetanephrine;
Pheochromocytoma;
Plasma;
Prospective Studies*
- From:Endocrinology and Metabolism
2015;30(4):481-487
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Current guidelines for follow-up of adrenal incidentalomas are extensive and hampered by lack of follow-up studies. We tested the hypothesis that small lipid-rich adrenal incidentalomas, initially characterized by tumor size <40 mm and <10 Hounsfield units (HUs) on unenhanced computed tomography (CT) may not demonstrate excessive growth/hormonal hypersecretion on follow-up. METHODS: Sixty-nine incidentalomas in 56 patients were restudied with unenhanced CT and screening for hypercortisolism (dexamethasone suppression test [DST], plasma adrenocorticotropic hormone) and pheochromocytoma (24-hour urinary metanephrines and normetanephrines) 5 years later. Primary hyperaldosteronism was excluded at base-line. RESULTS: Tumor (n=69) size was similar before and after 5 years follow-up (19+/-6 mm vs. 20+/-7 mm). Mean tumor growth was 1+/-2 mm. Largest increase in tumor size was 8 mm, this tumor was surgically removed and histopathology confirmed cortical adenoma. DST was normal in 54 patients and two patients (3.6%) were still characterized by subclinical hypercortisolism. Initial tumor size was >20 mm for the patient with largest tumor growth and those with subclinical hypercortisolism. All patients had normal 24-hour urinary metanephrines and normetanephrines. Low attenuation (<10 HU) was demonstrated in 97% of 67 masses re-evaluated with unenhanced CT. CONCLUSION: None of the patients developed clinically relevant tumor growth or new subclinical hypercortisolism. Biochemical screening for pheochromocytoma in incidentalomas demonstrating <10 HU on unenhanced CT is not needed. For such incidentalomas <40 mm, it seems sufficient to perform control CT and screen for hypercortisolism after 5 years.
